Precision testing is only as valuable as its timing. During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Hao Wang from Sichuan Cancer Hospital delivered a focused presentation on the optimal timing of endocrine-related molecular testing in patients with HR+/HER2– metastatic breast cancer.

On March 14, 2026, the international oncology journal Annals of Oncology (2025 IF: 65.4), the official journal of the European Society for Medical Oncology (ESMO), published the results of the international multicenter phase III OPTIMAL trial (NCT03315364). The study was led by Academician Binghe Xu (first author) from the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Professor S-B. Kim (corresponding author), with key contributions from Professor Tao Sun (Liaoning Cancer Hospital) and Professor H. Jeong (Asan Medical Center, University of Ulsan College of Medicine), among other international collaborators. For the first time, the study demonstrated that oral paclitaxel (DHP107) is non-inferior to weekly intravenous paclitaxel in first-line treatment of HER2-negative recurrent or metastatic breast cancer, with lower neurotoxicity and greater convenience—offering patients a safer and more accessible therapeutic option.

Antibody–drug conjugates (ADCs) are reshaping the treatment landscape of breast cancer at an unprecedented pace. From HER2 to Trop-2, and from late-line metastatic settings to early-stage neoadjuvant therapy, ADC indications continue to expand while efficacy breakthroughs accumulate. Oncology Frontier invited Professor Jian Zhang from Fudan University Shanghai Cancer Center and Professor Songqing Ye from Fujian Provincial Hospital to engage in an in-depth discussion on the evolution of ADCs, recent clinical advances, toxicity management, and future trends. Drawing on cutting-edge clinical data and real-world experience, the two experts offer valuable insights into efficacy optimization, toxicity management, frontline integration, combination strategies, and drug diversification.

With the arrival of spring, the 8th Tongji Breast Cancer Forum was successfully convened, focusing on key topics including clinical needs, cutting-edge advances, grassroots implementation, and the development of young physicians. The meeting not only built a bridge for in-depth dialogue between leading experts and frontline clinicians, but also offered fresh perspectives on integrating clinical practice with the latest scientific progress.

From April 10 to 12, 2026, the National Breast Cancer Conference will be held in Beijing. Marking the 10th anniversary of the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC), this annual flagship meeting will once again bring together leading experts from China and around the world to share cutting-edge research, interpret the latest guidelines and consensus statements, and exchange clinical experience—driving the high-quality development of breast cancer care in China. On the eve of the conference, Oncology Frontier invited Professor Zefei Jiang, Conference Chair and President-Elect of CSCO, to provide insights into the past decade of CSCO BC, the highlights of this year’s meeting, and key updates in the 2026 guidelines. We look forward to welcoming you in Beijing.